Rychlé odkazy
Kategorie
Odběr a výroba plazmy
Learn more about plasma collection and discover certified plasma centers near you.
Časopis The Source
Subscribe to the international magazine of the plasma protein therapeutics industry.
Informační listy
Fact sheets provide additional information about the global plasma protein therapeutics industry.
Často kladené otázky o plazmě
Get answers about plasma therapies and the processes surrounding donation and collection procedures.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Sep 23, 2020
U.S. International Trade Commission Testimony on COVID-19 Related Goods
Oral Testimony of Amy C. Efantis, President & CEO, Plasma Protein Therapeutics Association Hearing on COVID-19 Related Goods: Conditions in the U.S. Industry and Key Supply Chains U.S. International Trade Commission.
All
Advocacy
https://cdn.prod.website-files.com/638f893112c6eac0e46ac576/6453fa440e4694729840b893_PPTA_USITC_Testimony-COVID-19_.pdf
Sep 23, 2020
U.S. International Trade Commission Testimony on COVID-19 Related Goods
Oral Testimony of Amy C. Efantis, President & CEO, Plasma Protein Therapeutics Association Hearing on COVID-19 Related Goods: Conditions in the U.S. Industry and Key Supply Chains U.S. International Trade Commission.
All
Advocacy
https://cdn.prod.website-files.com/638f893112c6eac0e46ac576/6453fa440e4694729840b893_PPTA_USITC_Testimony-COVID-19_.pdf
Sep 15, 2020
Proposals for revision of donor deferral criteria in the context of the COVID-19 situation in order to maintain access to plasma-derived medicinal products for patients in EU
Proposals for revision of donor deferral criteria in the context of the COVID-19 situation in order to maintain access to plasma-derived medicinal products for patients in EU
All
Advocacy
https://cdn.prod.website-files.com/638f893112c6eac0e46ac576/64522eeace0c39bce531cdfd_%2315EMA20011a_IPFA-PPTA_letter_to_EMA_Donor_acceptance_Criteria15SEP2020_Final.pdf
Sep 15, 2020
Proposals for revision of donor deferral criteria in the context of the COVID-19 situation in order to maintain access to plasma-derived medicinal products for patients in EU
Proposals for revision of donor deferral criteria in the context of the COVID-19 situation in order to maintain access to plasma-derived medicinal products for patients in EU
All
Advocacy
https://cdn.prod.website-files.com/638f893112c6eac0e46ac576/64522eeace0c39bce531cdfd_%2315EMA20011a_IPFA-PPTA_letter_to_EMA_Donor_acceptance_Criteria15SEP2020_Final.pdf
Sep 1, 2020
The Source Fall 2020
Magazine of the plasma protein therapeutics industry - Fall 2020
All
The Source Magazine
https://drive.google.com/file/d/1H5xC-s8nFHylmAxW3kjTM4oZkN-cwNv7/view?usp=sharing
Sep 1, 2020
The Source Fall 2020
Magazine of the plasma protein therapeutics industry - Fall 2020
All
The Source Magazine
https://drive.google.com/file/d/1H5xC-s8nFHylmAxW3kjTM4oZkN-cwNv7/view?usp=sharing
Aug 5, 2020
PPTA Repeats Appeals for Plasma Donations
The Plasma Protein Therapeutics Association is steadfast in its mission to promote the availability of, and access to, safe and effective plasma protein therapies for patients around the world. We call on all eligible adults to donate plasma – whether you are someone recovered from COVID-19 or not, your plasma is needed to save lives, now. By donating plasma today, you are directly helping to save the lives of babies born with primary immune deficiencies, bleeding disorders, and other rare conditions, as well as patients who rely on plasma therapies in emergency and critical-care contexts.
All
PPTA statements
Aug 5, 2020
PPTA Repeats Appeals for Plasma Donations
The Plasma Protein Therapeutics Association is steadfast in its mission to promote the availability of, and access to, safe and effective plasma protein therapies for patients around the world. We call on all eligible adults to donate plasma – whether you are someone recovered from COVID-19 or not, your plasma is needed to save lives, now. By donating plasma today, you are directly helping to save the lives of babies born with primary immune deficiencies, bleeding disorders, and other rare conditions, as well as patients who rely on plasma therapies in emergency and critical-care contexts.
All
PPTA statements
No results found